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Although it has had only limited psychometric assessment in one country (the UK), the Psoriasis Disability Index
(PDI) is a commonly used measure of the impact of psoriasis on patients. This study’s objective was to analyze the
psychometric properties of the PDI in 1196 US patients. High Cronbach’s a coefﬁcients suggested that the PDI’s
internal consistency is good. The validity of the PDI was tested using a global question on disease burden and self-
assessed extent of disease and both appeared to be good predictors of the PDI. Large ﬂoor effects and the
suboptimal response distribution of most items, however, suggested that the PDI is insensitive to mild functional
limitation. Factor analyses indicated that the current PDI subscales are suboptimal. In the Rasch analysis, the PDI
and its subscales appeared to measure multiple constructs, making the validity of deriving a single overall score
questionable. The frequent presence of differential item functioning related to several patient characteristics con-
ﬁrmed the instrument’s multidimensionality. These ﬁndings suggest that the PDI is not an optimal measure for use
in US study populations. The psychometric properties of instruments designed to measure the impact of psoriasis
should be tested in populations in which the instrument is to be applied.
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Psoriasis is an incurable skin condition that affects about
2% of the population (Stern et al, 2004). Measures of clinical
severity of psoriasis may not reflect patients’ perceptions of
the impact of the disease on their lives (De Korte et al, 2004;
Sampogna et al, 2004). Health-Related Quality of Life
(HRQOL) impairment is important in assessing psoriasis
severity (Krueger et al, 2000). The impact of psoriasis on
HRQOL may be comparable with that of other common
chronic conditions (Finlay and Coles, 1995; Rapp et al,
2000).
The measurement of HRQOL_provides valuable infor-
mation about disease burden to various decision makers,
including clinicians and researchers, third-party payers,
technology assessment groups, and government regulatory
bodies. These measures are also often utilized in psoriasis
clinical trials providing the patients’ perspective on the ef-
fectiveness of therapies. Although several instruments have
been available to assess the impact of psoriasis (Naldi et al,
2003; De Korte et al, 2004), the psychometric properties of
these instruments are not fully known (Ashcroft et al, 1998).
Psychometrics is the science of measurement of abstract
concepts or ideas such as intelligence, well-being or quality
of life (QOL) and its properties reflect different aspects of the
instrument’s performance in a study population (Streiner,
1994; Chren et al, 1999). Moreover, the utility of these
measures and cross-cultural differences in patient popula-
tions with varying disease severity or demographic charac-
teristics are generally unknown (Bullinger et al, 1993; Koo,
1996; Chren, 1999; Guyatt et al, 2002; Choi and Koo, 2003;
Tennant et al, 2004a). Understanding the characteristics
of tools used to measure patients’ perceptions (Testa and
Simonson, 1996; Chren, 1999) is important for interpreting
studies accurately and applying them to clinical care and
decision making (Williams, 2003; Chren and Weinstock,
2004).
The Psoriasis Disability Index (PDI) was one of the at-
tempts to quantify the impact of psoriasis on patients’ lives
(Finlay and Kelly, 1987) and is the most commonly used
disease-specific instrument for this purpose (De Korte et al,
2002; Naldi et al, 2003). Its psychometric properties have
been partially tested in the UK using different patient pop-
ulations and different versions of the instrument, (Finlay and
Kelly, 1987; Finlay et al, 1990; Kent and Al-Abadie, 1993;
Finlay and Coles, 1995; O’Neill and Kelly, 1996). With the
exception of a factor analysis conducted on a reduced ver-
sion of the PDI (Kent and Al-Abadie, 1993), assessments of
its scaling structure in relation to internal consistency, factor
analysis, Rasch analysis, and differential item functioning
(DIF) have not been reported.
Abbreviations: DIF, differential item functioning; HRQOL, Health-
Related Quality of Life; PDI, Psoriasis Disability Index; QOL, quality
of life
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Although the PDI has been used in surveys and clinical
trials in several countries (O’Neill and Kelly, 1996; Finlay,
1997; van de Kerkhof et al, 2000; Zachariae et al, 2002),
including the US (Gelfand et al, 2005), the psychometric
properties of this instrument in US patients are unknown
(Choi and Koo, 2003). Such an assessment is crucial, as
concepts, assessments, and relevance statements about
constructs such as HRQOL may vary dramatically by cul-
ture or national context (Bullinger et al, 1993; Tennant et al,
2004a).
In response to this, this study examined the psychomet-
ric properties of the PDI, including its consistency, validity,
and dimensional structure, using data from a recent survey
of approximately 1200 US psoriasis patients.
Results
Study participants Of a total of 1861 respondents, 1196
(64.3%), who were 18 or older and reported having been
diagnosed with cutaneous psoraisis without psoriatic ar-
thritis by a physician, completed the PDI questionnaire. Of
these, 19.4% were from the general population, 30.6%
were members of the Psoriasis Foundation, and 50.1%
were individuals who had contacted the Foundation but
were not members. The three samples differed in age, an-
nual income, extent, and global burden of disease (Nijsten
et al, 2005a). Most study participants were middle-aged
whites with longstanding psoriasis (Table S1). Almost half
reported needing three palms or more to cover their pso-
riasis. Participants who were working (full- or part-time)
were significantly (po0.001) more likely to be older and
male than those not working. Otherwise, patient character-
istics did not differ substantially with employment status.
Response distribution of PDI The percentage of ques-
tionnaires with one or with more than one item missing were
10.5% and 2.5%, respectively. Items were answered by at
least 96.5% of subjects.
Of the 1196 persons, 85.4% responded ‘‘not at all’’ to at
least half (eight of 15) of the PDI items (Fig 1). Nine items
demonstrated a suboptimal response distribution, with
X70% of participants choosing the same response cate-
gory (Fig 1). All PDI subscales had small ceiling effects
(p5%) but substantial floor effects (X49%), except daily
activities (Table I).
An analysis of mixtures demonstrated that the PDI’s dis-
tribution was a mixture of five independent distributions
(maximized log-likelihood¼1553.69) (Table II). This result-
ed in five categories of disability: none (PDI score 0), little
(PDI score 1–4), moderate (PDI score 5–9), large (PDI score
10–18), and very large (PDI score 418). The validity of this
categorization, which includes the validity of the PDI, was
confirmed by comparing the PDI categories (I–V) with de-
gree of global disease burden in everyday life and extent of
disease (p-values for trend o0.01).
Validity of the PDI Total PDI score increased significantly
(po0.001) with increasing problems in everyday life score
(Fig 2). The correlation between the total PDI score and the
global question was moderately high (r¼ 0.65). In contrast
with the global item, the range of the PDI and its subscales
scores were not fully used (Table S2). For example, the
6.9% of the patients who scored 10 of 10 on the global item
reported a median score on the total PDI of 19.0 (25th per-
centile¼9.0 and 75th percentile¼26.25) suggesting that
the upper third range of the PDI score is not optimally used.
The PDI was significantly (po0.001) related to extent of
disease (Fig 2) (r¼ 0.50 for PDI score and extent of disease).
Consistency of the PDI The a values and the item–rest
score correlations suggest that the internal consistency of
the PDI subscales was adequate (Table I). The correlation
coefficients between items in a subscale and other sub-
scales (range r: 0.21–0.56) were comparable with the item–
rest coefficients (Table I) suggesting low discriminant valid-
ity; however, no PDI item correlated more strongly with an-
other subscale than with its own subscale (data not shown).
Of the 17 items, only three (items 4, 8, and 14) failed to
demonstrate a correlation of 0.40 or above with any of the
other items (Table S3). The correlation coefficients between
the subscales ranged from 0.39 to 0.61.
Dimensionality of the PDI Both parallel analyses and min-
imum average partial tests identified two factors for working
and one for nonworking respondents (Table III), which ac-
counted for 45.3% and 41.6% of the total PDI variance,
respectively. For working people, the first factor may reflect
work-related disabilities and the second factor may reflect
hygiene and embarrassment. One factor was retained that
loaded 0.40 or more for all but items 4 and 14, which in-
dicated item complexity, among those not working. For
working people the, uniqueness of items 4, 8, and 14 was
Figure1
Distribution of response to each of the items of the Psoriasis Dis-
ability Index.
666 NIJSTEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
very high (X0.70) suggesting that these items’ variances
were not well captured by the retained factors.
The Rasch analysis of the total PDI scale yielded poor
overall fit of the data to the model (item–trait interaction
w2¼429.9 (df¼ 153; po0.001)). Examination of individual
item fit highlighted six items with a w2 statistic o0.05 and
a standardized residual above 2.5 or less than 2.5 (Table
S4). An additional four items showed misfit according to one
of these two criteria. Problems were particularly evident
with the items of the daily activities and, to a lesser extent,
the leisure subscales. When the daily activities, work, and
leisure subscales were analyzed separately, misfit remained
for many of the daily activities items, suggesting problems
with the items themselves (within-subscale item fit in Table
S5). Individual item misfit was also evident in the work and
leisure subscales. These findings indicate violations of the
assumption of unidimensionality for the individual subscales
and the overall PDI.
DIF was examined in relation to sex, age, employment
status, extent of disease, and level of disease burden (Table
S5). Several items were found to exhibit some degree of DIF
within each of the patient characteristics examined, with the
exception of employment status. DIF was most evident in
relation to age, with 11 of 17 items showing variations by this
factor. Eight items were found to function differently by more
than one factor. Items 4 and 15 were particularly problematic
in this regard, with variations in responses at the same level
of disability by four of the five patient characteristics.
Discussion
Response distribution In contrast to a British study that
observed substantially greater variance in the distribution of
responses of items (Finlay and Coles, 1995), a broad sam-
ple of US psoriasis patients were likely to indicate that they
were ‘‘not at all’’ affected by their psoriasis for most of the
items. The large floor effect associated with many items
suggests that the PDI provides limited information about
how disability among US patients varies, particularly for
those reporting low levels of disability because of their
psoriasis. This discrepancy between British and US patients
may reflect the heterogenous and probably more generally
representative nature of our sample, which was not limited
to patients seen in a hospital setting or undergoing a spe-
cific therapy. But restricting the sample to the 156 individ-
uals with 10 palms or more of psoriasis did not overcome
the problem; floor effects remained high (25.0%–75.6%).
These persistent floor effects suggest that other issues may
Table I. Distribution of scores of the Psoriasis Disability Index (PDI) and its subscales
PDI and
its scales
No. of items
(range of score)
Mean (SD, 25th, and
75th percentiles) % ﬂoor % ceiling
Item–rest
correlationb Cronbach’s a
PDI 15 (0–45) 7.3 (7.2, 2.0, 11.0) 14.7 0.0 — —
Daily activities 5 (0–15) 3.5 (3.2, 1.0, 5.8) 20.5 0.2 0.35–0.59 0.78
Work 3 (0–9) 0.8 (1.5, 0.0, 1.0) 63.8 0.3 0.45–0.56 0.81
Personal 2 (0–6) 0.7 (1.2, 0.0, 1.0) 67.6 1.0 0.52–0.53 0.80
Leisure 4 (0–12) 1.9 (2.6, 0.0, 3.0) 49.3 0.2 0.33–0.56 0.77
Treatment 1 (0–3) 0.7 (0.8, 0.0,1.0) 52.9 4.5 —a —a
aScale consists of one item.
bCorrelation of an item with all other items within a subscale.
Figure 2
Box plots of the Psoriasis Disability Index score stratified to (A)
problem in everyday life score and (B) extent of disease.
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play a role in the distribution of item responses. Social an-
thropological studies have demonstrated that concepts,
assessments, and relevance statements about constructs
such as QOL may vary dramatically by culture or national
context (Bullinger et al, 1993). The interpretation of scoring
systems may also differ between cultures (Bullinger et al,
1993; Stern, 2003; Tennant et al, 2004a).
Although the PDI may be useful in evaluating therapies for
moderate-to-severe psoriasis, our results suggest a relative
lack of sensitivity, which implies that it is an inappropriate
instrument to be used in clinical trials for those with limited
disease (Wall et al, 1998; Gupta et al, 1999; Hutchinson et al,
2000; Andreassi et al, 2003; Woo et al, 2003). Both our re-
spondents and those in a Scandinavian survey (Zachariae
et al, 2002) with limited disease reported lower PDI scores
with high floor effects (data not shown) suggesting it is also
an insensitive measurement tool in general population sur-
veys (O’Neill and Kelly, 1996; van de Kerkhof et al, 2000;
Zachariae et al, 2002; Gelfand et al, 2005). This study dem-
onstrated that the PDI should be used cautiously in interna-
tional collaborations (Tennant et al, 2004a) and modifications
are needed to improve its sensitivity for US studies.
Validity and consistency of PDI There is no gold standard
for HRQOL measurements. Therefore, assessing their va-
lidity is a multifaceted, iterative process (Guyatt et al, 1992;
Chren, 1999). Although clinically assessed disease severity
may not always correlate well with the degree of HRQOL
impairment (De Korte et al, 2004; Sampogna et al, 2004),
this study confirmed previous findings that the PDI appears
to be able to discriminate between individuals with different
severities of disease in British (Finlay and Kelly, 1987; Finlay
et al, 1990; Finlay and Coles, 1995) and US (Gelfand et al,
2005) samples. Furthermore, comparison with a global
score of disease burden supported the PDI’s validity. In
contrast to the global question, the higher half to a third of
the range of the PDI and its subscales is unused, which
confirms its poor sensitivity and discriminant ability.
Dimensionality of the PDI The PDI items were originally
grouped into five subscales on a ‘‘common-sense’’ basis
and may have some degree of face validity (Finlay et al,
1990); however, this structure could not be confirmed by
factor analysis (Kent and Al-Abadie, 1993) and may reflect
the limited number of items in some of the PDI subscales.
Nevertheless, the lack of fit to the Rasch model indicates
that the PDI is not unidimensional. Multidimensionality of a
psychometric tool compromises its additivity and thus the
validity of creating an overall score (Tesio, 2003; Conrad and
Smith, 2004; Tennant et al, 2004b). Moreover, the presence
of DIF, indicates that persons with the same degree of pso-
riasis-related disability but who differ with respect to differ-
ent gender or age are not likely to score in a similar way on
these items. This implies that the PDI is not intrinsically
generalizable in heterogenous populations, which suggest
that comparison of the PDI scores of these different patient
groups may not be appropriate. Although self-assessed
global disease burden and extent of disease were associ-
ated with PDI scores, the lack of unidimensionality raises
questions about the validity of the measure (Tesio, 2003;
Conrad and Smith, 2004; Tennant et al, 2004b). Attempting
to identify a valid dimensional structure for the PDI is, how-
ever, beyond the scope of this study.
HRQOL instruments in clinical trials In psoriasis trials,
instruments commonly used to assess patients’ perspec-
tives of the efficacy of therapy include the PDI, Short Form-
36, and the Dermatology Life Quality Index (Naldi et al,
2003; De Korte et al, 2004). At present, the lack of a well-
tested and widely accepted psoriasis-specific HRQOL in-
strument has led to the use of multiple health status end-
points to assess patients’ perception of the effectiveness of
a therapy in a single study (Gordon et al, 2003). Although
generic or dermatology-specific HRQOL instruments may
be useful in assessing the impact of psoriasis on patients’
lives, adding a psoriasis-specific HRQOL instrument is pre-
ferred because it should be more clinically sensitive, provide
a higher correlation with disease severity and be more re-
sponsive to changes in effect of the disease over time
(Patrick and Deyo, 1989; Chren, 1999; Choi and Koo, 2003;
De Korte et al, 2004). Although the PDI appears to be rea-
sonably valid and reliable in the assessment of psoriasis-
associated disabilities in patients with moderate-to-severe
disease, its psychometric properties appear to be subop-
timal. Moreover, the PDI falls short of providing an overall
assessment of the impact of the condition and its treatment
on the patient (Finlay and Kelly, 1987; Koo, 1996; De Korte
et al, 2002; McKenna et al, 2003). High-quality, disease-
specific, patient-based outcome measures are needed for
robust assessments of psoriasis therapies. These instru-
ments should be validated across cultures and for a broad
range of psoriasis severities. Because of the impact of in-
tercultural differences (Bullinger et al, 1993; Tennant et al,
2004a), the development of an optimal HRQOL instrument
may be even more challenging than choosing a measure of
clinical disease severity. New psoriasis-specific measures
such as the Psoriasis Index of Quality of Life (PSORIQoL;
McKenna et al, 2003) and the Psoriasis Quality of Life
Questionnanaire (Choi and Koo, 2003) have been devel-
oped, but they have not yet been widely tested across cul-
tures or in diverse patient populations.
Strengths and limitations A strength of this study is its
large, heterogenous sample including patients with varying
disease severity. Although the results of this study may not
be fully representative of the general population, subanal-
yses of the three patient groups suggested that the PDI is
likely to do worse in patients from the general population
(data not shown). This is an attempt to test fully the psy-
Table II. Analysis of mixtures of the Psoriasis Disability Index
score and its categorization
Category of
disability Weight Mean Range
% of patients
(n¼ 1196)
I. None 0.17 0.26 0 14.7
II. Little 0.29 2.95 1–4 31.4
III. Moderate 0.26 6.48 5–9 23.8
IV. Large 0.20 12.58 10–18 21.0
V. Very large 0.09 23.71 19–45 9.1
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chometric properties of the PDI, including internal consist-
ency, factor analysis, and Rasch modelling and DIF in a
heterogenous sample of US patients. Previous studies have
tested its validity (Finlay and Kelly, 1987; Finlay et al, 1990;
Finlay and Coles, 1995) and determined its underlying struc-
ture (Kent and Al-Abadie, 1993) in UK patient populations.
As a convenience sample, this study is subject to pos-
sible biases and other limitations including diagnostic bias
and imprecision in the assessment of extent of disease and
global burden (Stern et al, 2004; Nijsten et al, 2005a,b;
Gelfand et al, 2005). To enhance diagnosis accuracy and to
reduce confounding because of disability from arthritis (Kay
et al, 2003), the analysis was restricted to individuals re-
porting only cutaneous disease. Because the PDI was ad-
ministered once to the participants, we were unable to
determine test–retest reliability, instrument’s responsive-
ness, or its minimal important difference.
Conclusion
The PDI was one of the disease-specific HRQOL instru-
ments to be developed in dermatology and has contributed
greatly to our understanding of the patient’s perspective of
psoriasis. Nevertheless, this study suggests that it is not
well targetted to measuring disease impact among patients
with low levels of disability. Also, the unidimensionality and
the generalizability of the total scale and the underlying
structure of the subscales could not be confirmed. The
psychometric properties of instruments designed to assess
the overall impact of a disease and its treatments on pa-
tients’ lives should be thoroughly tested in populations that
vary culturally, demographically, and in disease severity be-
fore they are recognized as valid HRQOL assessment tools.
Methods
Design and participants The survey design, setting, and study
participants are described in detail elsewhere (Stern et al, 2004;
Gelfand et al, 2005; Nijsten et al, 2005a,b). Briefly, in 2001, the
National Psoriasis Foundation commissioned two survey research
companies to interview patients with psoriasis. The subjects in-
cluded came from two random samples: one drawn from the gen-
eral population using random digit dialing, one drawn from the
database of the National Psoriasis Foundation that registered
members and people who had contacted the Foundation but did
not join it. The study sample is a convenience sample. Eligibility
required that interviewees reported having been diagnosed with
psoriasis by a physician. Individuals were contacted independently
of extent of disease, type of psoriasis, level of disability, use of
therapies, or treating physician. This analysis was restricted to re-
spondents who were aged 18 or older with psoriasis without
psoriatic arthritis.
To estimate functional lifestyle disabilities caused by psoriasis,
the second version of the PDI (Finlay and Coles, 1995) was used.
The PDI uses a categorical rating scale, with responses of ‘‘not at
all,’’ ‘‘a little,’’ ‘‘a lot,’’ and ‘‘very much’’ scored 0, 1, 2, and 3,
respectively. In line with the instrument guidelines, missing items
Table III. Factor analyses of Psoriasis Disability Indexa,b
Scales Items
Persons who were working (n¼ 985)
Persons who were
not working (n¼211)
Factor I
(eigenvalue¼5.46)
Factor II
(eigenvalue¼ 1.33) Uniquenessc
Factor I
(eigenvalue¼ 6.24) Uniquenessc
Daily activities 1. House/garden work 0.56 0.25 0.60 0.62 0.42
2. Different clothes 0.17 0.56 0.59 0.53 0.62
3. Wash/change clothes 0.33 0.53 0.50 0.65 0.44
4. Hairdresser problem 0.11 0.47 0.73 0.35 0.65
5. More baths 0.26 0.48 0.63 0.64 0.44
Work 6a. Time off work 0.70 0.12 0.49 — —
7a. Inhibit work 0.77 0.23 0.35 — —
6b. Less activity — — — 0.77 0.29
7b. Different activity — — — 0.79 0.28
8. Career affected 0.21 0.27 0.76 0.52 0.60
Personal
relations
9. Sex difficulties 0.24 0.59 0.55 0.63 0.43
10. Social relations 0.38 0.58 0.53 0.63 0.44
11. Social activities 0.45d 0.62 0.43 0.80 0.30
12. Sport difficult 0.21 0.51 0.45 0.69 0.35
Leisure 13. Communal changing 0.21 0.51 0.61 0.58 0.47
14. More smoke/drink 0.21 0.37 0.78 0.32 0.78
Treatment 15. Home messy/untidy 0.30 0.51 0.64 0.57 0.52
aPrincipal axis method followed by oblique rotation (promax) of factors that were selected using parallel analysis and minimum average partial tests.
bIn bold, the items that are best represented (factor loading40.40) by each factor.
cFor each item, uniqueness represents the proportion of variance that is not explained by the retained factors.
dAlthough a factor loading greater than 0.40, it is not in bold because the loading is higher for the second factor.
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Table IV. Definitions of some of the test characteristics and statistical methods used in this studya
Statistical methods and test characteristics Definitiona
Differential item functioning (DIF) This test assesses the impact of patient characteristics (also referred to as personal
factors) such as gender and age on individual items of the measurement tool. For
example, do patients with the same degree of disability respond differently to an item
because they differ by gender or age? If the p-value of the analysis of variance of
standardized residuals across a factor was less than 0.05, an item was defined as
having significant DIF, which suggests that an item lacks generalizability in populations
that span different patient groups
Exploratory factor analysis This statistical approach is used to test whether the proposed subscaling of an existing
instrument is appropriate. The number of factors derived from the analysis reflects the
number of different constructs being measured by the instrument. The cluster of items
that load on the same factor forms a subscale. An item belongs to a factor
(i.e., subscale) if its loading is greater than 0.40 (see also item complexity)
‘‘Floor-and-ceiling’’ effect If more than 20% of the patients reported lowest or highest possible score of an
instrument’s (sub)scale, respectively, the (sub)scale is likely to be insensitive
Item complexity If an item ‘‘loads heavily on’’ (i.e., is strongly correlated with) a factor (i.e., a subscale) in
an exploratory factor analysis (see above) it should belong to that factor and not to any
other. If it loads on none or two or more factors then it is likely that it may be tapping
something other than what the developer intended. Suboptimal complexity was said to
exist if the highest loading of an item was less than 0.40 or if the difference between
the loadings on different factors was less than 0.10
Internal consistency Assesses the degree of correlation of a patient’s responses to items enquiring about
similar constructs. For each subscale (i.e., a construct), Cronbach’s a, which is based
on average inter-item correlation and number of items, was calculated. If the a was
less than 0.70, the internal consistency was considered suboptimal for each subscale’s
items
Item–rest correlation Spearman’s correlation coefficients (r) of each item with the sum of the other items in
that subscale were calculated to check the homogeneity of the (sub)scales.b Suboptimal
item–rest correlation was defined as ro0.20.
Item–discriminant validity We compared the item–rest correlation coefficients with the correlation coefficients of
an item with the other subscales. If the former equalled or was smaller than the latter,
an item was defined as having poor discriminant validity
Item–trait interaction An overall summary fit statistic, which is a formal test of invariance to the scale. It
evaluates whether or not the data fit the Rasch model for the discrete groups (class
intervals) along the scale. If the w2 p-value is 40.05, it suggests that the data fit the
Rasch model
Mixture analysis This statistical method is used to determine whether multiple, distinct subdistributions
are present in the overall distribution of the scores of all the individuals. Subsequently,
it can be used to categorize each observation in one of the distinct subdistributions and
thus creates categories
Parallel analysis and minimum average partial test Statistical methods used in factor analysis to determine which limited number of
factors should be retained to contain the maximum amount of information
The Rasch model The Rasch model is a unidimensional model that has two main assertions: that the
milder the health problem is, the more likely it will be affirmed, and the more impaired
the patient, the more likely they will be to affirm a health problem compared with a
less impaired patient. Where data fit the Rasch model unidimensionality is confirmed
and order, additivity and specific objectivity (i.e., sample-free measurement) result
Item fit of the Rasch model Two statistical approaches are used to test whether the individual items fit
the Rasch model:
Residual A function of the difference between respondents’ observed item responses
and the ones predicted by the model, expressed in ‘‘logits’’ (log-odds units).
If located between 2.5 and þ2.5, it suggests that an item fits the Rasch model
p-value A goodness-of-fit w2 statistic that assesses the discrepancy between the
expected and actual response pattern across respondents. p40.05 suggests
that an item fits the Rasch model
Response distribution An item was described as having a poor distribution if more than 70% of patients
chose the same response, indicating that the item is not sensitive
aFor references, see Methods section.
bBased on the factor analysis.
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were scored ‘‘0.’’ The higher the summed score (range: 0–45), the
greater the limitations experienced because of psoriasis. In addi-
tion to the total score, the PDI has five subscales: daily activities,
work, personal relations, leisure, and treatment. All items were
identical for all respondents except that out of a possible five work
items, respondents completed only 3; those who were working
(either full- or part-time) responded to items 6a, 7a, and 8, whereas
those who were not working responded to items 6b, 7b, and 8.
Participants were also asked to rate psoriasis as a ‘‘problem
in everyday life’’ using a 10-point Likert scale (1¼ no problem to
10¼ a very large problem) (Likert, 1932). Although not shown, a
mixture model (Haughton, 1997; Boehning and Schlattmann, 2004)
was used to group responses as follows: 1–4¼ ‘‘little burden’’ and
5–10¼ ‘‘substantial burden.’’ In addition to questions about de-
mographic and disease characteristics, respondents were asked
to estimate the number of palms needed to cover all their psoriasis
at the time of the interview (little or none, 1–2, 3–10 or 410 palms).
The survey was granted exempt status by an independent IRB.
Statistical methods
Response distribution For each item, the response distribution
(Streiner, 1994; Chren et al, 1997) and for each subscale, the
‘‘floor’’ and ‘‘ceiling’’ effects were assessed (Anderson et al, 1997)
(Table IV). To categorize the PDI score, a mixture analysis was used
(Table IV) (Haughton, 1997; Boehning and Schlattmann, 2004).
First, we estimated the weights, which reflect the proportion of the
total variance of a scale, for the maximum number of grid points
assuming Poisson distributions. In this case, we entered the min-
imum and maximum PDI scores to calculate the number of grid
points which are used as a first estimate for the support points. All
grid points with positive weight together with the corresponding
weights were used as starting values for the expectation–maxim-
ization algorithm. So, in this phase, weights as well as support
points, which are parameters of the distinct subdistributions, were
estimated. Then a much smaller number of weights and support
points were computed with a nonparametric maximum likelihood
estimator. Because some support points were extremely close to
each other, we combined identical parameters with an accuracy of
0.01. This procedure resulted in a number of support points and
weights that were then entered into a fixed mixture analysis to
classify each observation in one of the different mixture compo-
nents using posterior probabilities.
Consistency of the PDI For each subscale, several item per-
formance features such as Cronbach’s a (Cronbach, 1951), item–
rest correlations (Chren et al, 1997), and item–discriminant validity
were determined (Haley et al, 2004) (Table IV).
Validity of the PDI Construct validity, which hypothesizes logical
relations that should exist between patients’ characteristics and
their responses to an instrument, was assessed through conver-
gent validity and known groups validity (Streiner, 1994; Chren et al,
1999). Convergent validity was established by assessing the de-
gree to which PDI scores were associated with the global ‘‘problem
in everyday life’’ item. Spearman’s correlation coefficient was used
to assess the correlation between the global item and the total PDI
and its subscales. Known groups validity assessed the ability of
the PDI to distinguish between groups that differed according to
the extent of their disease (none or little, 1–2, 3–10, and 410
palms), which we expected would be correlated with PDI scores.
The Kruskal–Wallis test was used to test for statistical differences
between the groups.
Dimensionality of the PDI To identify constructs accounting for
variability in responses to the items of the PDI, an exploratory fac-
tor analysis (Table IV) was conducted for persons who were work-
ing and for those who were not working, separately (Gorusch,
1974). The principal axis method was used for the initial extraction
of factors. We hypothesized that the subscales were correlated
and, therefore, performed an oblique rotation (promax). Rotation
modifies the result of the initial factor analysis to create a set of
loadings that are often more interpretable than those produced by
the factor analysis. We used parallel analyses and minimum av-
erage partial tests (Zwick and Velicer, 1986; O’Connor, 2000) to
limit the number of factors (Table IV).
Rasch analysis also examined the subscale structure of the PDI
because data fit to the model suggests unidimensionality (Table IV)
(Rasch, 1960; Tesio, 2003; Conrad and Smith, 2004; Tennant et al,
2004b). The overall fit of the data was assessed estimating the
item–trait interaction and the individual item fit by calculating a w2
statistic and a standardized residual (Table IV). Such analyses were
conducted for the total PDI scale and its subscales, except for the
personal relations and treatment subscales which have too few
items. In addition, differential item functioning (Table IV) (Angoff,
1993; Tesio, 2003; Tennant et al, 2004b), which may also be a
potential source of violation of unidimensionality, was evaluated in
relation to various factors including: sex, age, employment status,
extent of disease, and disease burden.
All statistical tests were two sided. Significance was assessed
at an a level o0.05. Stata version 7.0 (Stata, College Station, Tex-
as) was used to estimate Cronbach’s a, the correlation coefficients
and the principal axis analyses. SPSS version 10.0 for Windows
(SPSS, Chicago, Illinois) was used to determine the number of
retained components (O’Connor, 2000). Assessments of unidim-
ensionality and DIF through the Rasch analysis were performed
using RUMM2010 (RUMM Laboratory, Perth, Australia). To cate-
gorize the PDI, computer-assisted analysis of mixtures 2.0 (Haugh-
ton, 1997; Boehning and Schlattmann, 2004) was used.
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